Surgery Partners (SGRY) Cash & Equivalents (2014 - 2026)

Surgery Partners has disclosed Cash & Equivalents across 13 years of filings, most recently posting $216.7 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 13.35% year-over-year to $216.7 million; the TTM figure through Jun 2026 stood at $216.7 million (down 13.35% YoY), while the FY2025 annual figure was $239.9 million, down 10.98% from the prior year.
• Cash & Equivalents came in at $216.7 million for Q2 2026 at Surgery Partners, up from $182.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $378.9 million in Q1 2022 to a low of $154.8 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $228.4 million, with a median of $224.6 million recorded in 2022.
• Year-over-year, Cash & Equivalents sank 53.15% in 2022 and jumped 52.45% in 2023.
• Over 5 years, Cash & Equivalents stood at $282.9 million in 2022, then plunged by 30.75% to $195.9 million in 2023, then jumped by 37.57% to $269.5 million in 2024, then dropped by 10.98% to $239.9 million in 2025, then declined by 9.67% to $216.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $216.7 million in Q2 2026, $182.3 million in Q1 2026, and $239.9 million in Q4 2025.